文献速递妇科

仑伐替尼联合帕博利珠单抗对比化疗用于铂类治疗后复发性错配修复完整型子宫内膜癌的成本效果

Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy.
PubMed 文献 · Gynecol Oncol · 2024-01-22

该研究建立马尔可夫模型模拟1万例复发性错配修复完整(pMMR)子宫内膜癌患者,比较仑伐替尼联合帕博利珠单抗与化疗(多柔比星或剂量密集紫杉醇)的成本效果。结果显示联合治疗2年生存人数更多(367 vs 109),但成本更高(193,590 vs 66,693美元),ICER为164,493美元/QALY;联合治疗成本每月降低1553美元(降幅7.8%)时才具成本效果。

要点

  • 仑伐替尼联合帕博利珠单抗2年生存人数367例,化疗109例。
  • 化疗成本66,693美元,联合治疗193,590美元,ICER为164,493美元/QALY。
  • 联合治疗成本每月降低1553美元(7.8%)时才具成本效果。

核心结论

  • 对于复发性pMMR子宫内膜癌患者,仑伐替尼联合帕博利珠单抗生存获益更大但成本高于化疗。
  • 仑伐替尼和帕博利珠单抗的成本需降低约7%才被认为具有成本效果。

研究设计与样本

  • 研究建立马尔可夫模型模拟10,000例复发性pMMR子宫内膜癌患者的临床轨迹。
  • 模型初始决策点为仑伐替尼联合帕博利珠单抗或化疗(多柔比星或剂量密集紫杉醇)。
  • 模型概率、效用值和成本基于已发表文献的假设,周期长度3个月,时间跨度2年。
  • 效果以平均获得的质量调整生命年(QALYs)计算,主要结局为增量成本效果比(ICER),以2020年美元/QALYs表示。
  • 进行单因素、双因素和概率敏感性分析。

主要发现

  • 化疗是最低成本策略,成本66,693美元,其次为仑伐替尼联合帕博利珠单抗193,590美元。
  • 仑伐替尼联合帕博利珠单抗使更多患者2年时存活(联合治疗367例 vs 化疗109例)。
  • 化疗相比仑伐替尼联合帕博利珠单抗具有成本效果(ICER:164,493美元/QALYs)。
  • 当仑伐替尼联合帕博利珠单抗成本每月降低1553美元(降幅7.8%)时,联合治疗变得具有成本效果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The recent Study 309-KEYNOTE-775 showed improved survival for lenvatinib plus pembrolizumab compared to chemotherapy in patients with recurrent endometrial cancer. We created a decision model to compare the cost-effectiveness of lenvatinib plus pembrolizumab in patients with recurrent mismatch repair-proficient (pMMR) endometrial cancer who had progressed after first-line chemotherapy. METHODS: A Markov model was created to simulate the clinical trajectory of 10,000 patients with recurrent pMMR endometrial cancer. The initial decision point in the model was treatment with ether lenvatinib plus pembrolizumab or chemotherapy (doxorubicin or dose-dense paclitaxel). Model probabilities, utility values and costs were derived with assumptions drawn from published literature. A cycle length of 3 months and a time horizon of 2 years was used. The effectiveness was calculated in terms of average quality adjusted life years (QALYs) gained. The primary outcome was incremental cost-effectiveness ratios (ICERs), expressed in 2020 US dollars/QALYs. One-way, two-way and probabilistic sensitivity analyses were performed. RESULTS: Chemotherapy was the least costly strategy at $66,693 followed by lenvatinib plus pembrolizumab ($193,590). Lenvatinib plus pembrolizumab resulted in more patients being alive at 2 years (lenvatinib plus pembrolizumab: 367, chemotherapy: 109). Chemotherapy was cost-effective compared with lenvatinib plus pembrolizumab (ICER: $164,493/QALYs). Lenvatinib plus pembrolizumab became cost-effective when its cost was reduced by $1553 per month (7.8% reduction). CONCLUSION: For patients with recurrent pMMR endometrial cancer Lenvatinib plus pembrolizumab is associated with greater survival but is more costly than chemotherapy. The cost of lenvatinib and pembrolizumab would have to be reduced by approximately 7% to be considered cost-effective.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Dioun S, Chen L, De Meritens AB, et al. Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy. Gynecol Oncol. 2024. PMID: 38262241. doi:10.1016/j.ygyno.2023.12.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。